the future of ravulizumab in nmosd
Published 1 year ago • 144 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
1:39
recent progress and future needs in nmosd treatment
-
3:00
unmet needs in the diagnostics and treatment of nmosd
-
40:06
2019 rnds — the future of nmosd therapeutics: what have we learned?
-
3:22
efficacy subgroup analyses from the phase iii champion-nmosd trial
-
10:36
spheres: collecting real-world data to explore disease characteristics & clinical outcomes in nmosd
-
5:44
diagnostic criteria and treatment updates for nmosd
-
1:51
selecting treatment options for nmosd
-
2:44
updates on n-momentum: inebilizumab versus placebo in patients with nmosd
-
2:18
predictors of early serologic diagnosis of aq4-igg positive nmosd
-
2:59
an overview of the current treatment options for nmosd from actrims 2024
-
1:49
satralizumab in patients with nmosd and concomitant autoimmune diseases
-
3:11
anti-c5 mab eculizumab highly efficacious for the treatment of aqp4-positive nmosd
-
1:21
novel treatment strategies for nmosd
-
2:05
long term safety and efficacy data for ravulizumab in achr ab generalized myasthenia gravis
-
3:29
status of nmosd in latin america
-
1:30
key research questions in seronegative nmosd
-
6:18
soliris® (eculizumab) mechanism of action for neuromyelitis optica spectrum disorder (nmosd)
-
2:26
pregnancy planning: differences between counselling nmosd and ms patients
-
21:23
2022 pre-rnds | neuromyelitis optica spectrum disorder (nmosd)